Briviact®
In Europe, Briviact® (brivaracetam) is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
January, 2016
Top of this page
Skip navigation, go straight to the content
